FA and OCT work best in combination

Article

Although fluorescein angiography (FA) and optical coherence tomography (OCT) are both effective ways to detect macular oedema (ME), when used in isolation they may miss subtle manifestations of the condition, according to a study published in the April 2008 issue of Retina.

Although fluorescein angiography (FA) and optical coherence tomography (OCT) are both effective ways to detect macular oedema (ME), when used in isolation they may miss subtle manifestations of the condition, according to a study published in the April 2008 issue of Retina.

Igor Kozák, MD of the Jacobs Retina Center, University of California San Diego, US and colleagues conducted a 12-month retrospective single-centre study of 1272 eyes undergoing simultaneous FA and OCT to diagnose ME.

The team found that, in 94.97% of cases (n=1208), a diagnosis of ME was confirmed by both techniques. In 3.86% of cases (n=49), FA indicated ME while OCT indicated a normal result; OCT indicated ME where FA indicated normal results in 1.17% of eyes (n=15).

Thus the researchers concluded that FA and OCT, whilst both highly sensitive and effective techniques, have a very small percentage of discrepancies when detecting ME.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases during the American Society of Retina Specialists (ASRS) annual meeting
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.